Skip to content

Determination of the efficacy of artemisia extraction dressing on the healing of diabetic foot ulcer

Comparison of healing effect of aqueous extract from one Artemisia spp on diabetic foot ulcer with classic treatment: a clinical trial.

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT201105236565N1
Enrollment
18
Registered
2011-07-06
Start date
2010-11-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic foot. Diabetes mellitus

Interventions

Intervention 1: The test group will receive topical Artemisia extraction, twice a day, and follow up weekly for 2months or until the complete healing of the wounds. Evaluation of diameter, percentage
Treatment - Drugs
The test group will receive topical Artemisia extraction, twice a day, and follow up weekly for 2months or until the complete healing of the wounds. Evaluation of diameter, percentage of healing and m
The control group will received classic treatments for diabetic foot ulcer, and follow up weekly for 2 months or until the complete healing the wound. Evaluation of diameter, percentage of healing and

Sponsors

Vice chancellor for research, Kermanshah University Of Medical Sciences and Health Services
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Presence of diabetic foot ulcer in type 1 or 2 diabetes mellitus patient;age between 18 and 75 years with diabetic foot ulcer;The ulcer of the the patients have been caused by peripheral neuropathy; uncontrolled hyperglycemia;trauma; diabetic foot ulcers which remained open without healing and/or improvement for at least 2 week;Patients should be available for 2 months and to be able to adhere to the treatment regime. Exclusion criteria:patients with =Grade III Wagner classification diabetic foot ulcers;evidence of systemic or local infection such as purulent drainage and osteomyelitis; erythema in the edge of wound with 3 centimeter width and exposed bone at the wound site; sever and chronic ischemia of lower limb without presence of pulsation;simultaneous diseases which had impact on healing process such as vasculitis or different types of cancers;hepatic or renal failure;endocrine;hematological or immunologic disorder;past history of/current acute or chronic autoimmune disease;chronic alcohol or drug abuse;immunosuppressive drugs;cytotoxic agents;radiation therapy and chemotherapy were excluded.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Diameter reduction rate. Timepoint: Weekly for 2 months. Method of measurement: Evaluation of diameter with precise measurement with digital photo.

Secondary

MeasureTime frame
Percentage of complete healing. Timepoint: Weekly for 8 week. Method of measurement: Evaluation of percentage of complete healing with precise measurement with Digital photo.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Gholam Reza Bahrami

Kermanshah University of Medical Science

gbahrami@kums.ac.ir+98 83 1428 1562

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026